ClinicalTrials.gg

Program

FH-006

A development code. Also written as “FH-006 for Injection” and “FH-006; SHR-1316 ; SHR-8068”.

Its studies are mostly in Lung Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Aug 25, 20264 company-led studies, 4 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine44 open or runningphase 3since Aug 25, 2026Dec 6, 2024Feb 2027phase 2 · NCT07136142

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 6, 2024First study: phase 2 study in Malignant Solid TumorFirst studyNCT06735144 · 200 planned · China
  2. Aug 14, 2025Phase 2 study in Malignant Solid TumorNCT07136142 · 150 planned · China
  3. Nov 14, 2025Phase 2 study in Lung NeoplasmsNCT07241767 · 200 planned · China
  4. Aug 25, 2026Phase 3 study in RecurrencePhase 3 reachedNCT07790380 · 480 planned · China

Ahead

  1. Feb 2027Primary completion: phase 2 study in Malignant Solid TumorNCT07136142
  2. Nov 2027Primary completion: phase 2 study in Lung NeoplasmsNCT07241767
  3. Dec 2027Primary completion: phase 2 study in Malignant Solid TumorNCT06735144
  4. Jun 30, 2029Primary completion: phase 3 study in RecurrenceNCT07790380

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07790380Recurrence · China3RecruitingJun 30, 2029480
NCT07241767Lung Neoplasms · China2RecruitingNov 2027200
NCT07136142Malignant Solid Tumor · China2RecruitingFeb 2027150
NCT06735144Malignant Solid Tumor · China2RecruitingDec 2027200

How it is read

Names in the registry

  • “FH-006”, 3 entries
  • “FH-006 for Injection”, 1 entry
  • “FH-006; SHR-1316 ; SHR-8068”, 1 entry

Codes read as this program: FH006.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.